Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility

Kaname Kawajiri, Junko Watanabe, Hidetaka Eguchi, Shin Ichi Hayashi

Research output: Contribution to journalArticlepeer-review

54 Citations (Scopus)

Abstract

A close association of smoking-associated lung cancer incidence with the Msp I and lle-Val polymorphisms of CYP1A1 gene was found in a Japanese population in terms of genotype frequency comparison and cigarette dose response. A synergistic increase in susceptibility to lung cancer was observed when the susceptible genotypes of CYP1A1 were combined with a deficient GSTM1 genotype. Individual difference in expression levels of Ahr and Arnt mRNAs was observed, and the expression levels of CYP1A1 appeared to associate with those of transcriptional factors. The Ahr protein has two different structures, ascribed to one amino acid replacement at codon 554 of Arg by Lys. However, this germ line polymorphism did not show a significant association with AHH inducibility nor lung cancer incidence. The p53 gene alterations in lung cancer tissues were more frequently observed among the patients with a susceptible allele of CYP1A1 gene.

Original languageEnglish
Pages (from-to)S70-S73
JournalPharmacogenetics
Volume5
DOIs
Publication statusPublished - 1995 Dec
Externally publishedYes

ASJC Scopus subject areas

  • Genetics
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint

Dive into the research topics of 'Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility'. Together they form a unique fingerprint.

Cite this